slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 56,821-56,850
Pages 3,679
Rows per page 30
Component
56,821-56,850 of 110,355
17
The chart uses a dual-line comparison to show the impact of the pandemic on product demand.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
18
The slide uses a combination of a bar chart for annual revenue and a line chart for monthly prescription volume to demonstrate product performance.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
19
The slide uses a combination of a summary table and a grouped bar chart to demonstrate competitive outperformance.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
20
Includes clinical efficacy/safety data and commercial value proposition.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
Includes detailed footnotes regarding data sources and limitations.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
22
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a two-column list structure to categorize launch activities.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
34
The slide highlights board independence, diversity, and tenure metrics alongside governance updates.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
36
The slide uses a 2x2-style grid layout to contrast commercial products with development pipeline candidates.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
50
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
51
The slide uses a structured table to categorize drug development candidates by their biological mechanism.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
52
The slide uses molecular modeling imagery to illustrate different engineering approaches (Mutation, Fusion, ScFv Bispecific, Fusionbody, IgG Bispecific).Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
60
Uses a Venn-like diagram to contrast existing therapy strategies with new development strategies.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
62
Data cutoff March 1, 2021. PR=partial response, RP2D=Recommended Phase 2 Dose.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
68
The slide uses a structured clinical case format to demonstrate drug efficacy.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
71
The slide uses a two-column layout to contrast disease burden with treatment limitations, supported by extensive clinical citations.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
77
RP2D = Recommended Phase 2 Dose; SC = Subcutaneous; q7d = every 7 days.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
78
The slide uses a three-column layout to summarize clinical safety data.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
81
Patient profile includes diagnosis, prior treatment history, current study activity, and clinical outcomes.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
83
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
90
The diagram illustrates the biological process from tumor cell death to T-cell activation.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
91
The slide uses a vertical process diagram to illustrate the mechanism of ICD.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
92
The slide uses a biological process flow diagram to explain the therapeutic rationale.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
93
The slide demonstrates synergistic effects of combination therapy on immune cell infiltration.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
94
The chart demonstrates synergy between the two treatments.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
95
The slide presents two key metrics: tumor volume over time and Kaplan-Meier survival curves.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
96
The slide uses a vertical process diagram to explain the biological mechanism of ICD.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
97
The slide uses a 'problem-solution' structure, identifying the dual nature of chemo/radiation and proposing Nemvaleukin as a counter-measure.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
102
The slide uses a diagram to illustrate the biological pathway from IL-12 to immune cell activation and subsequent downstream effects.Alkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit
103
Alkermes | Investor Day Presentation Deck | 144 slidesAlkermes | Investor Day Presentation Deck | 144 slides · Alkermes
Conference presentation Investor relations 1 hit